BUZZ-Arvinas 因与诺华达成前列腺癌药物许可协议而上涨

Reuters04-11

((自动化翻译由路透提供，请见免责声明 ))

4月11日 - ** 药物开发商Arvinas 股价盘前上涨3.5%至38美元

** 该公司与诺华签订了 (link) 战略许可协议，在全球范围内开发和商业化其名为 ARV-766 的前列腺癌实验药物。

** 根据协议，ARVN 将获得高达 10.1 亿美元的商业里程碑以及 ARV-766 的分级特许权使用费

** 交易还包括向诺华公司购买公司临床前 AR-V7 项目的资产购买协议

** ARVN 将获得 1.5 亿美元的预付款，用于 ARV-766 的许可和 AR-V7 项目的销售

** 截至收盘，ARVN股价年累计下跌10.8

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2426258783?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-04-11 19:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2426258783","market":"us","top_or_hot":-1,"title":"BUZZ-Arvinas 因与诺华达成前列腺癌药物许可协议而上涨","media":"Reuters","content":"<html><body><p>((自动化翻译由路透提供，请见免责声明 ))</p><p>    4月11日 - ** 药物开发商Arvinas   股价盘前上涨3.5%至38美元</p><p>** 该公司与<a href=\"https://laohu8.com/S/NVS\">诺华</a>  签订了 (link) 战略许可协议，在全球范围内开发和商业化其名为 ARV-766 的前列腺癌实验药物。</p><p>** 根据协议，ARVN 将获得高达 10.1 亿美元的商业里程碑以及 ARV-766 的分级特许权使用费</p><p>** 交易还包括向诺华公司购买公司临床前 AR-V7 项目的资产购买协议</p><p>** ARVN 将获得 1.5 亿美元的预付款，用于 ARV-766 的许可和 AR-V7 项目的销售</p><p>** 截至收盘，ARVN股价年累计下跌10.8 </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Arvinas 因与诺华达成前列腺癌药物许可协议而上涨</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Arvinas 因与诺华达成前列腺癌药物许可协议而上涨\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-11 19:31 北京时间&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>((自动化翻译由路透提供，请见免责声明 ))    4月11日 - ** 药物开发商Arvinas   股价盘前上涨3.5%至38美元** 该公司与诺华  签订了 (link) 战略许可协议，在全球范围内开发和商业化其名为 ARV-766 的前列腺癌实验药物。** 根据协议，ARVN 将获得高达 10.1 亿美元的商业里程碑以及 ARV-766 的分级特许权使用费** 交易还包括向诺华公司购买公司...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0211331839.USD","symbol_name":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2426258783","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2426258783","pubTimestamp":1712835096,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"((自动化翻译由路透提供，请见免责声明 ))    4月11日 - ** 药物开发商Arvinas   股价盘前上涨3.5%至38美元** 该公司与诺华  签订了 (link) 战略许可协议，在全球范围内开发和商业化其名为 ARV-766 的前列腺癌实验药物。** 根据协议，ARVN 将获得高达 10.1 亿美元的商业里程碑以及 ARV-766 的分级特许权使用费** 交易还包括向诺华公司购买公司临床前 AR-V7 项目的资产购买协议** ARVN 将获得 1.5 亿美元的预付款，用于 ARV-766 的许可和 AR-V7 项目的销售** 截至收盘，ARVN股价年累计下跌10.8","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4007":"制药","ARVN":"Arvinas Holding Company LLC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4532":"文艺复兴科技持仓","NVS":"诺华","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4578":"CAR-T","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4585":"ETF&股票定投概念","BUZZ":"VanEck Social Sentiment ETF","BK4588":"碎股"},"translate_title":"BUZZ-Arvinas rises on license deal with Novartis for prostate cancer drug","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BUZZ":1,"NVS":1,"ARVN":0.9},"content_text":"((自动化翻译由路透提供，请见免责声明 ))    4月11日 - ** 药物开发商Arvinas   股价盘前上涨3.5%至38美元** 该公司与诺华  签订了 (link) 战略许可协议，在全球范围内开发和商业化其名为 ARV-766 的前列腺癌实验药物。** 根据协议，ARVN 将获得高达 10.1 亿美元的商业里程碑以及 ARV-766 的分级特许权使用费** 交易还包括向诺华公司购买公司临床前 AR-V7 项目的资产购买协议** ARVN 将获得 1.5 亿美元的预付款，用于 ARV-766 的许可和 AR-V7 项目的销售** 截至收盘，ARVN股价年累计下跌10.8","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2426258783"}